Article
Molecular characterization of squamous cell carcinoma of the anal canal
1 Oct 2021
Abstract excerpt
Background: Squamous cell carcinoma of the anal canal (SCCA) is an uncommon malignancy with limited therapeutic options. Nivolumab and pembrolizumab show promising results in patients with SCCA. Human papillomavirus (HPV)-negative tumors are frequently TP53-mutated (TP53-MT) and often resistant to therapy. Methods: We present a large molecularly-profiled cohort of SCCA, exploring the underlying biology of SCCA,...
Topics
Join the communities discussing this publication.
